TECregen
About Us
Our Mission
Founders & Leadership
Board of Directors
Scientific Advisory Board
Investors and Partners
Our Science
News
Contact
News
29th January, 2026
TECregen Appoints Drug Development Veteran Dr. Klaas P. Zuideveld as Chief Executive Officer to Lead Thymus Regeneration Platform into Clinical Development
8th January, 2026
TECregen Raises CHF 10 Million in Seed Financing and Appoints Dr. Bo Rode Hansen as Chairman
